Soumyajeet Paul

Soumyajeet Paul

Auto-generated profile, based on publicly available information

Soumyajeet Paul

Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka-576104, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
BJB.S. Jayashree
B.S. Jayashree
PNP. Sai Nikhil
P. Sai Nikhil
SPSoumyajeet Paul
Soumyajeet Paul
Bioisosterism is a unique approach used by medicinal chemists for the reasonable modification of lead compounds into safer, more clinically effective, economical, and therapeutically attractive drugs. It is one of the most crucial lead modification tools, widely applied in the field of rational drug design to amplify the desired activity and eliminate undesirable properties, thus facilitating the optimization of pharmacokinetic profile and achievement of target selectivity. This review demonstrates the importance of bioisosterism in the process of drug discovery and development and highlights its relevance in the molecular evolution of many classes of drugs such as antibacterial sulfonamides, anticancer drugs, antivirals, antifungals, anthelmintics, local anesthetics, barbiturates, antidepressants, antihistamines, proton pump inhibitors and work carried out by our team of researchers. The role of bioisosterism as a strategy to achieve inhibition of enzymes such as thymidylate synthase, DNA polymerase, reverse transcriptase and several others has also been pointed out. There are no limits to the classes of drugs where bioisosterism has been successfully applied.

1 December 2023 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SPSoumyajeet Paul
Soumyajeet Paul
RJRamaiah Selladurai Jeyaprakash
Ramaiah Selladurai Jeyaprakash
APAravinda Pai
Aravinda Pai
HVHillemane Venkatachalam
Hillemane Venkatachalam
BJBellur Srinivas Jayashree
Bellur Srinivas Jayashree
Calixarenes have always captured the attention of several researchers. They have the ability to entrap multiple molecules and form inclusion complexes with drugs due to their unique structure. Due to this property, they are being widely used in the development of several classes of drugs, most notably anticancer drugs. This review attempted to summarize the potential applications of calixarenes and its derivatives in the development of anticancer drugs, with a focus on the delivery of drug classes such as DNA intercalators, taxanes, DNA alkylators, and topoisomerase inhibitors. Calixarene-based macromolecular chemistry could therefore have a high potential for overcoming the toxicity of cancer chemotherapy and achieving targeted drug delivery.

30 June 2026 in Postgraduate Medicine
Verified
Journal Article
Open access
ARAsha K Rajan
Asha K Rajan
MOMaria Ioana Onofrei
Maria Ioana Onofrei
ARAnanya Rudra
Ananya Rudra
SPSoumyajeet Paul
Soumyajeet Paul
VSVishal Shanbhag
Vishal Shanbhag
GTGirish Thunga
Girish Thunga
Optimizing colistin dosing in patients with renal impairment, particularly those undergoing renal replacement therapy (RRT), remains a major challenge due to complex and variable pharmacokinetics. This systematic review identifies key covariates affecting pharmacokinetics of colistimethate sodium (CMS) and its active form colistin and evaluates dosing variability in patients with renal impairment, including those receiving RRT. Systematic searches of PubMed, Embase, Scopus, and Cochrane Library (up to November 2025) identified studies reporting the pharmacokinetics of intravenous CMS, formed colistin or colistin sulfate (nebulized CMS used as adjuvant in some studies) in adults with renal impairment or on RRT. Data on dosing regimens, dialysis characteristics, pharmacokinetic parameters, and covariates were extracted, and methodological quality was appraised using validated pharmacokinetic criteria. Thirteen studies (n = 450) met inclusion. CMS clearance was primarily determined by renal function and dialysis-related parameters were the most consistent determinants of pharmacokinetics, while additional covariates such as cystatin C, ALT, hematocrit, and body weight were identified in individual studies. In patients undergoing SLEDD, extracorporeal clearance was reported to account for up to 67% of total drug clearance in a single study. Standardized CMS dosing regimens often failed to achieve pharmacodynamic targets for formed colistin (fAUC/MIC ≥12). Colistin pharmacokinetics in patients with renal impairment and those receiving renal replacement therapy are highly variable and influenced by both renal and non-renal factors, including dialysis modality. Standard dosing regimens frequently fail to achieve pharmacodynamic targets, highlighting the need for individualized, physiology-based dosing strategies. Integration of renal function, RRT parameters, and emerging biomarkers such as cystatin C, alongside therapeutic drug monitoring, is essential to optimize efficacy while minimizing toxicity in this high-risk population. www.crd.york.ac.uk/prospero identifier is CRD42021294141.